J.P. Rowan

No ORCID on file · 6 papers in corpus
article 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
·doi:10.1056/nejmoa1700089

Copyright © 2017 Massachusetts Medical Society. BACKGROUND Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, …

article 2016
Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies
·doi:10.1016/j.fertnstert.2016.07.780
article 2016
The effect of elagolix on bone mineral density: safety results from two randomized, placebo-controlled studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2016.07.794
article 2016
The effect of elagolix on the endometrium: safety results from two randomized, placebo-controlled studies in women with endometriosis-associated pain
·doi:10.1016/j.fertnstert.2016.07.274
article 2016
The impact of elagolix on quality of life in women with endometriosis-associated pain: results from two randomized, placebo-controlled studies using the endometriosis health profile questionnaire
·doi:10.1016/j.fertnstert.2016.07.271
article 2016
Use of elagolix for the management of endometriosis-associated pain: secondary efficacy results from two randomized, placebo-controlled studies
·doi:10.1016/j.fertnstert.2016.07.774